Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 4Neoplasms 3Carcinoma 3Thoracic Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Neoplasms, Nerve Tissue 2Neoplasms by Site 2Neoplasms by Histologic Type 2Lung Diseases 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Adenocarcinoma 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1NSCLC 1Mesothelioma, Malignant 1Hemangioendothelioma, Epithelioid 1EGFR-mutated NSCLC (Disorder) 1

Interventions

osimertinib 2Pemetrexed 2Carboplatin 2pralsetinib 1pembrolizumab 1Sunitinib 1Paclitaxel 1Gemcitabine 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasms, Nerve Tissue × osimertinib × Clear all
NCT04862780 2025-02-10

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Blueprint Medicines Corporation

Phase 1 Terminated
177 enrolled
Thoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05153408 2023-06-18

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Blueprint Medicines Corporation

Phase 1 Terminated
20 enrolled
Thoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡